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Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the major global health issues, strongly
correlated with insulin resistance, obesity and oxidative stress. The current study aimed to evaluate
anti-NAFLD effects of three different extracts of Phyllanthus niruri (P. niruri). NAFLD was induced
in male Sprague–Dawley rats using a special high-fat diet (HFD). A 50% methanolic extract (50%
ME) exhibited the highest inhibitory effect against NAFLD progression. It significantly reduced
hepatomegaly (16%) and visceral fat weight (22%), decreased NAFLD score, prevented fibrosis,
and reduced serum total cholesterol (TC) (48%), low-density lipoprotein (LDL) (65%), free fatty
acids (FFAs) (25%), alanine aminotransferase (ALT) (45%), alkaline phosphatase (ALP) (38%), insulin
concentration (67%), homeostatic model assessment of insulin resistance (HOMA-IR) (73%), serum
atherogenic ratios TC/high-density lipoprotein (HDL) (29%), LDL/HDL (66%) and (TC–HDL)/HDL
(64%), hepatic content of cholesterol (43%), triglyceride (29%) and malondialdehyde (MDA) (40%)
compared to a non-treated HFD group. In vitro, 50% ME of P. niruri inhibited α-glucosidase,
pancreatic lipase enzymes and cholesterol micellization. It also had higher total phenolic and
total flavonoid contents compared to other extracts. Ellagic acid and phyllanthin were identified as
major compounds. These results suggest that P. niruri could be further developed as a novel natural
hepatoprotective agent against NAFLD and atherosclerosis.
Keywords: Phyllanthus niruri; non-alcoholic fatty liver disease (NAFLD); insulin resistance;
atherosclerosis; α-glucosidase; pancreatic lipase; cholesterol micellization; ellagic acid; phyllanthin
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome,
which is highly associated with several metabolic disorders such as type 2 diabetes mellitus (T2DM),
insulin resistance (IR) and hyperlipidemia [1,2]. In the absence of excessive alcohol ingestion, obesity
is one of the major etiological factors of NAFLD, which is characterized by an accumulation of
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triglycerides inside the liver cells to a percentage exceeding 5% of liver weight [3], with the same
histopathological manifestations of an alcoholic liver injury [4]. During the last two decades, its
prevalence has reached worrying proportions as it has come to affect 25.2% of the people worldwide [5],
including 20–30% of adults and 3–10% of children in Western countries [6]. NAFLD was reported
as the main factor in many of the morbidities related to liver diseases [7]. It causes various types of
liver injuries, including simple hepatic fat accumulation, which may occur alone or associated with
steatohepatitis, known as non-alcoholic steatohepatitis (NASH), with or without fibrosis [8,9]. It was
suggested by several studies that NAFLD is the key player in increasing the incidence of hepatocellular
carcinoma [10]. The pathogenesis of NAFLD is multifactorial, but it is mainly attributed to insulin
resistance and imbalance in lipids (uptake, hepatic synthesis and degradation) [9]. Recently, gut
dysbiosis has also been linked with NAFLD [11].
Insulin resistance and oxidative stress are essential risk factors for NAFLD [12,13]. Oxidative
stress promotes the production of reactive oxygen species (ROS) that stimulate an inflammatory
process in hepatic tissues [14]. On the other hand, insulin resistance inhibits the antilipolytic activity of
insulin in the adipose tissue and increases free fatty acids (FFAs) in the serum and liver, leading to
mitochondrial dysfunction as well as cardiac fat accumulation [15].
Over the last decade, several noteworthy research initiatives have aimed at finding possible
therapies to ameliorate the hepatic damage that accompanies NAFLD. The majority of pharmacological
strategies include using antioxidant agents and insulin sensitizers, and also reducing the effect of
dietary carbohydrate and fats by the inhibition of cholesterol micellization, pancreatic lipase and
α-glucosidase [16–18].
Recently, a considerable number of studies has investigated natural phytochemicals as
anti-NAFLD agents [19–22]. P. niruri, a herb found in South East Asia, has been traditionally used to
treat many pathological conditions like dyspepsia, bronchitis, influenza, asthma, dysentery, tumours,
diabetes, vaginitis and tuberculosis [23]. It was also used for its potent activity in the treatment of
kidney stones and gallstones [24] and various liver disorders, particularly hepatitis and jaundice.
Recent data showed that P. niruri had hepatoprotective properties against induced hepatitis in rats [25],
and it has a therapeutic effect on T2DM, which is associated with hypercholesterolemia [26].
P. niruri is rich in flavonoids and phenolic compounds that are responsible for its potent
antioxidant properties [27], which could play important roles in hepatoprotective activity [28,29].
However, to the best of our knowledge, no reports have been published regarding the therapeutic
effects of P. niruri in the treatment of NAFLD. Thus, in this study we attempt to evaluate the potential
role of P. niruri in suppressing and/or ameliorating the development of NAFLD induced by the oral
administration of a high-fat diet (HFD) in rats as a model that reflects human NAFLD, using metformin
as the positive control drug.
2. Materials and Methods
2.1. High-Fat Diet Preparation
A normal diet was purchased from Gold Coin Feed mills Sdn. Bhd., Penang, Malaysia (product
code 702P), which contains crude protein (21–23%), crude fibre (5%), crude fat (3%), moisture (13%),
ash (8%), calcium (0.8%) and phosphorus (0.6–1.0%). The high-fat diet was prepared by mixing the
normal diet with 10% margarine (wt/wt), 10% ghee fat (wt/wt), 1% cholesterol and 0.5% cholic acid.
2.2. Extract Preparation
A specimen of P. niruri including whole plant was identified by Professor Mashhor Mansor from
the Botany Department, School of Biological Sciences, Universiti Sains Malaysia (USM). A voucher
herbarium specimen has been deposited at the Herbarium Unit (Voucher No. 11474), School of
Biological Sciences, USM. A powder of dry whole plant of P. niruri was extracted by maceration using
water (WE), 50% methanol in water (50% ME) and methanol (ME) respectively.
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2.3. In Vivo Model
The NAFLD animal model was developed and studied using 36 male Sprague–Dawley (SD) rats
(10 weeks of age), obtained from the Animal Research and Service Centre, USM. All experimental
procedures were carried out after getting the approval from Animal Ethics Committee, Universiti Sains
Malaysia (protocol No.: 2013/(90) (546)).
Animals were acclimatized for one-week and randomly assigned to six groups (n = 6). Group
1 was fed a normal diet for eight weeks and served as the normal control group (NC), while the
five remaining groups (2–6) were fed a high-fat diet (HFD) for eight weeks. Oral gavage treatment
started in week 4. Group 1was treated with distilled water (10 mL/kg body weight). Group 2 was
the HFD group, which served as a negative control and received distilled water (10 mL/kg body
weight); group 3 served as a positive control and received metformin (HFD + Met 500 mg/kg body
weight) at 10 mL/kg body weight; groups 4–6 received 1000 mg/kg of P. niruri WE, 50% ME, and ME,
respectively, at 10 mL/kg body weight
The same protocol was repeated for evaluating the dose-response relationship, using five groups.
Group 1 was fed a normal diet and served as a normal control group (NC), while the four remaining
groups were fed a high-fat diet (HFD) for eight weeks. Oral gavage treatment started in week 4. Group
1 was treated with distilled water (10 mL/kg body weight). Group 2 served as a negative control and
received distilled water (10 mL/kg body weight); groups 3, 4, and 5 received 1000 mg/kg, 500 mg/kg,
and 250 mg/kg, respectively, of the most active extract of P. niruri to evaluate the relative potency of
the three different doses (1000 mg/kg, 500 mg/kg, and 250 mg/kg) at 10 mL/kg body weight.
2.4. Determination of Blood and Serum Biochemical Parameters
After eight weeks of HFD feeding, all the rats were fasted overnight and the body weight of each
rat was determined. They were anesthetized with sodium pentobarbital (60 mg/kg intraperitoneal
(i.p.)). Five millilitres of the blood were taken via cardiac puncture from each rat. Blood glucose level
was determined using an automated blood glucose meter (Accu-chek Performa®, Roche Diagnostics,
Mannheim, Germany). Peri-renal fats were isolated and weighed for the assessment of visceral adipose
tissues. The serum was used to measure aspartate transaminase (AST), alanine transaminase (ALT),
alkaline phosphatase (ALP), total bilirubin, creatinine, uric acid, urea, low-density lipoprotein (LDL),
high-density lipoprotein (HDL), total cholesterol (TC), and triglycerides (TG) levels using the Olympus
AU640™ multifunctional biochemistry analyser (laboratories of Gribbles, Penang, Malaysia).
2.5. Determination of Insulin and Free Fatty Acids Concentrations
Insulin levels were determined using the commercial rat insulin ELISA kit (Elabscience
Biotechnology Co., Ltd., Beijing, China). Serum free fatty acids (FFAs) values were measured using a
fluorometric assay kit (Cayman Chemical, Ann Arbor, MI, USA) catalogue No. 700310.
2.6. Assessment of Atherosclerosis Risk Indexes
Recent data showed that NAFLD is one of the independent predictors of atherosclerosis [16].
Therefore, in order to identify high-risk cases of atherosclerosis and their effective therapeutic
management, the predictor ratios that complement the lipid profile ratios such as atherogenic Castelli’s
Risk Index I, Castelli’s Risk Index II, in addition to atherogenic coefficient (AC) were determined [30].
Atherogenic ratios were calculated based on the following formulas:
Castelli’s Risk Index-1 (CRI-I) = TC/HDL; (1)
Castelli’s Risk Index-2 (CRI-II) = LDL/HDL; (2)
Atherogenic Coefficient (AC) = (TC − HDL)/HDL. (3)
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2.7. Assessment of Lipid Peroxidation, TG and TC Contents in Liver Tissues
Total protein content of liver tissues was determined using a Bradford assay kit (Sigma-Aldrich,
San Jose, CA, USA). The MDA content was measured in the hepatic tissue homogenate by a
thiobarbituric acid reaction [31]. Hepatic lipid was extracted according to Folch et al. [32]. The content
of TG was determined using triglycerides colorimetric assay kit (Cayman Chemical, Ann Arbor, MI,
USA), while TC content was determined using a commercial kit according to the manufacturer’s
protocol (Thermo Fisher Scientific, Waltham, MA, USA).
2.8. Histopathological Examinations
For histological analysis, the liver specimen was taken from the largest hepatic lobe and fixed
with formaldehyde 10% (v/v). Histopathological examinations were performed by an experienced
pathologist using a blinded approach. The liver sections were stained with hematoxylin and eosin
(H&E). The histological features were examined and grouped into four broad categories: steatosis,
lobular inflammation, hepatocellular ballooning, and fibrosis. A score system was utilized to evaluate
each feature. An overall score, namely the NAFLD activity score (NAS), was generated based on the
individual scores of all the histological features [33].
2.9. Antioxidant Activity Tests
The antioxidant assays of the three extracts of P. niruri were carried out in triplicate at a
concentration of 10 mg/mL. Absorbance was measured using a microplate reader (TECAN Infinite
Pro® M200, Mannedorf, Switzerland). Total phenolic content (TPC) of each extract was estimated
using Folin-Ciocalteu reagent, according to the method of Kumaran and Joel Karunakaran [34].
Gallic acid was used as the standard. TPC was expressed as µg gallic acid equivalent/mg dry
extract. Total flavonoid content (TFC) of each extract was measured using the aluminium chloride
method [35]. Quercetin was used as a reference standard. TFC was expressed as µg quercetin
equivalent/mg dry extract. DPPH scavenging activity was assessed according to the method developed
by Al-Mansoub et al. [36]. Ascorbic acid was used as the reference standard. The scavenging activity
was expressed as IC50. ABTS scavenging activity was performed using the method described by
Al-Mansoub et al. [36]. Ascorbic acid was used as reference standard. Results were expressed as IC50.
The ferric reducing antioxidant power of each extract (FRAP) was carried out by the method of Benzie
and Strain [37]. All results were expressed as nmol Fe+2 equivalent/mg dry extract.
2.10. In Vitro Assay to Determine the Inhibitory Effects of the Most Active Extract on α-Glucosidase,
Pancreatic Lipase and Cholesterol Micellization
The inhibitory activity of the most active extract against α-glucosidase was measured based on
previous method described by Yusoff et al. [38] with minor modification. The results were expressed as
values of IC50 which is defined as the concentration of the sample/acarbose required to inhibit 50% of
α-glucosidase activity. Absorbance reading was taken using a microplate reader (TECAN Infinite Pro®
M200, Mannedorf, Switzerland). All analyses were done in triplicate. Six serial dilutions of each sample
were used to obtain the IC50 values. The inhibitory effect of the active extract towards pancreatic
lipase was assessed by fluorometric assay based on the method described by Zhang et al. [39,40], using
orlistat as the standard. The results were expressed as IC50 which is defined as the concentration of
either sample or orlistat required to inhibit 50% of pancreatic lipase activity.
The inhibitory activity of most active extract of P. niruri against cholesterol micelle formation was
carried out based on a previously reported method with minor modifications [41], using gallic acid as
the positive control and a total cholesterol test kit for cholesterol determination.
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2.11. Phytochemical Analysis by High-Performance Liquid Chromatography (HPLC)
To standardize the most active extract and further elucidate its chemical composition and active
compounds, an HPLC analysis was performed. Stock solutions (1000 µg/mL) of two selected marker
compounds (ellagic acid and phyllanthin) were prepared in methanol. The chromatographic separation
was carried out using a Zorbax Eclipse Plus C18 column and HPLC device (Agilent, Santa Clara, CA,
USA). Column specifications were 250 × 4.6 mm/5 µm particle size. The samples (10 µL) were eluted
at a flow rate of 1 mL/min at a λmax of 230 nm, with a gradient mobile phase comprising 0.2% aqueous
acetic acid and acetonitrile. The lowest limit of detection (LOD) value for each marker compounds
was determined by analysing the standard concentrations successively with a 2-fold dilution with
methanol. The concentration with the smallest detectable peak at a noise-to-signal ratio of 3 was
considered as the LOD value. Moreover, the lower linearity range limit at 83 noise-to-signal ratio of 10
was deemed as the limit of quantification (LOQ) [42]. Each working standard solution was injected
(n = 5) to determine the precision of the method. The values were expressed as the coefficient of
variation (CV%). Intra-day accuracy and precision analyses were carried out by injecting the working
standard concentrations (n = 5) within one day, whereas the intra-day analyses were conducted by
injecting the standard working concentrations once per day for five consecutive days (Murugaiyah
and Chan, 2007). Three working standard concentrations of each selected marker compound were
used to determine the percentage of recovery. The percentage of recovery was calculated for each
analyte according to the equation below [43]:
Recovery (%) = A − B/C × 100 (4)
where, A = amount of marker compound detected; B = original amount of the marker compound;
C = amount of the marker compound spiked.
Ellagic acid and phyllanthin were quantified in P. niruri extract. The extract (1 mg/mL) was
prepared in methanol for HPLC analysis. All the samples were filtered by 0.45 µm PTFE syringe filter.
The selected marker compounds were quantified in triplicates using linear regression equations of the
calibration curves.
2.12. Statistical Analysis
The results were expressed as means ± S.E.M. Statistical significant difference was examined
using Statistical Package of Social Sciences (SPSS) program, version 20 (IBM Corp., Armonk, NY,
USA). Differences between groups were evaluated using the one-way analysis of variance (ANOVA),
followed by Dunnett’s post hoc test, and was considered significant when p < 0.05.
3. Results
3.1. P. niruri Reduced Hepatomegaly and Visceral Adiposity
The results revealed that the liver to body weight ratio in the HFD group was 51.4% higher than in
the normal control (NC) group. Similarly, the visceral fat to body weight ratio was 48.6% higher in the
HFD group compared to the NC group (p < 0.01), indicating that HFD rats developed hepatomegaly
and visceral adiposity. These changes were reversed by metformin and 50% ME of P. niruri, both of
which significantly inhibited the increase in liver weight compared with the HFD group by 22.5%
(p < 0.01) and 15.8% (p < 0.05), respectively (Figure 1A), while the visceral fat weight was significantly
reduced in groups treated with metformin, WE, 50% ME, and ME of P. niruri by 28.7%, 24.9%, 22.5%,
and 26.5%, respectively, compared with the HFD group (Figure 1B).
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Figure 1. Effect of P. niruri extracts and metformin on liver weight and visceral fat ratios, serum liver 
enzymes and serum uric acid in high fat diet-fed rats. (A) Liver/body weight %; (B) visceral fat/body 
weight %; (C) ALP; Alkaline phosphatase; (D) ALT; Alanine aminotransferase; (E) AST/ALT; (F) 
serum uric acid. (Results expressed as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. HFD, 
and # p < 0.05, ## p < 0.01, ### p < 0.001 vs. NC group). NC; Normal control, HFD; High fat diet, Met; 
Metformin, WE; Water extract, MeE; Methanolic extract, SEM; Standard error mean.  
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To assess the development of NAFLD in the HFD model, the serum indicators correlated with 
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LDL, CRI-I, CRI-II, AC, and uric acid were significantly increased by 21.5%, 73.1%, 93.3%, 65.9%, 
92.7%, 90.2%, and 36.5%, respectively (all p < 0.01 except uric acid p < 0.05) in the HFD group when 
compared with the NC group. Moreover, liver enzymes including ALP and ALT levels were also 
rapidly doubled (both p < 0.01), with no significant effect on AST, while AST/ALT ratio was decreased 
by almost half in the HFD group as compared to the normal diet group. However, the changes 
induced by HFD in TG, HDL, AST, total bilirubin, creatinine and urea levels were not statistically 
significant. On the other hand, compared with the HFD group, treatment with metformin, WE, 50% 
ME, and ME of P. niruri has showed enhanced reduction in the levels of TC by 54.7%, 41.3%, 48.3%, 
and 41.6%, respectively. LDL was lowered by 74.65%, 57.13%, 64.68%, and 43%, respectively. CRI-II 
was reduced by 74.71%, 59.38%, 65.89%, and 41.43%, respectively. AC values were also decreased by 
73.3%, 58.9%, 64.4%, and 36%, respectively. However, only the treatment with metformin and 50% 
ME of P. niruri exhibited significant additional effects including the reduction of glucose by 21.2% 
and 15.5%, respectively; CRI-I by 46.7% and 29.3%, respectively; ALP levels by 57.6% and 38.3%, 
respectively; as well as improving AST/ALT ratios by 48% and 43.3%, respectively. ALT was 
significantly decreased in rats treated with metformin by 26.5%, ME of P. niruri by 28.8% (both p < 
0.05), and 50% ME 44.6% by (p < 0.01), whereas uric acid was significantly restored to normal value 
after treatment with WE and ME of P. niruri (p < 0.05). 
3.3. P. niruri Decreased FFAs and Insulin Resistance 
To evaluate the extent of insulin resistance in our model, we further measured the serum 
concentration of FFAs and insulin. Our results showed that eight weeks of oral administration of 
HFD has increased serum FFAs by 29.8% (p < 0.01), and serum insulin level by 68.8% (p < 0.01) and 
HOMA-IR by 75.7% (p < 0.01), indicating that rats the HFD developed distinct insulin resistance. 
However, treatment with metformin, WE, 50% ME, and ME of P. niruri markedly reduced FFAs by 
Figure 1. Effect of P. niruri extracts and metformin on liver weight and visceral fat ratios, serum liver
enzymes and serum uric acid in high fat diet-fed rats. (A) Liver/body weight %; (B) visceral fat/body
weight %; (C) ALP; Alkaline phosphatase; (D) ALT; Alanine aminotransferase; (E) AST/ALT; (F) serum
uric acid. (Results expressed as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. HFD,
and # p < 0.05, ## p < 0.01, ### p < 0.001 vs. NC group). NC; Normal cont l, HFD; High fat diet, Met;
Metformin, WE; Water extract, MeE; Methanolic extract, SEM; Standard error mean.
3.2. P. niruri Improved Abnormalities in Serum Indicators of NAFLD Rats
To assess the development of NAFLD in the HFD model, the serum indicators correlated with
NAFLD were measured. As shown in Figures 1 and 2 and Table 1, levels of glucose, total cholesterol,
LDL, CRI-I, CRI-II, AC, and uric acid were significantly increased by 21.5%, 73.1%, 93.3%, 65.9%, 92.7%,
90.2%, and 36.5%, respectively (all p < 0.01 except uric acid p < 0.05) in the HFD group when compared
with the NC group. Moreover, liver enzymes including ALP and ALT levels were also rapidly doubled
(both p < 0.01), with no significant effect on AST, while AST/ALT ratio was decreased by almost half
in the HFD group as compared to the normal diet group. However, the changes induced by HFD in
TG, HDL, AST, total bilirubin, creatinine and urea levels were not statistically significant. On the other
hand, compared with the HFD group, treatment with metformin, WE, 50% ME, and ME of P. niruri has
showed enhanced reduction in the levels of TC by 54.7%, 41.3%, 48.3%, and 41.6%, respectively. LDL
was lowered by 74.65%, 57.13%, 64.68%, and 43%, respectively. CRI-II was reduced by 74.71%, 59.38%,
65.89%, and 41.43%, respectively. AC values were also decreased by 73.3%, 58.9%, 64.4%, and 36%,
respectively. However, only the treatment with metformin and 50% ME of P. niruri exhibited significant
additional effect including the reduction of glucose by 21.2% and 15.5%, resp ctively; CRI-I by 46.7%
and 29.3%, resp tively; ALP levels by 57.6% and 38.3%, respectively; as well as improving AST/ALT
ratios by 48% and 43.3%, respectively. ALT was significantly decreased in rats reated with etformin
by 26.5%, ME of P. niruri by 28.8% (both p < 0.05), and 50% ME 44.6% by (p < 0.01), whereas uric acid
was significantly restored to normal value after treatment with WE and ME of P. niruri (p < 0.05).
3.3. P. niruri Decreased FFAs and Insulin Resistance
To evaluate the extent of insulin resistance in our model, we further measured the serum
concentration of FFAs and insulin. Our results showed that eight weeks of oral administration
of HFD has increased serum FFAs by 29.8% (p < 0.01), and serum insulin level by 68.8% (p < 0.01)
and HOMA-IR by 75.7% (p < 0.01), indicating that rats the HFD developed distinct insulin resistance.
However, treatment with metformin, WE, 50% ME, and ME of P. niruri markedly reduced FFAs by
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26.2%, 15.9%, 25.3%, and 32.5%, respectively, restored insulin levels to normal, and ameliorated insulin
resistance (Figure 2).
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levels of HOMA-IR; (D) serum levels of FFAs; (E) serum levels of LDL; (F) serum levels of TC. (Results 
expressed as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01; *** p < 0.001 vs. HFD, and # p < 0.05; ## p < 0.01; ### 
p < 0.001 vs. NC group). HOMA-IR; homeostatic model assessment of insulin resistance, FFAs; Free 
fatty acids, LDL; Low density lipoprotein, TC; Total cholesterol. 
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Figure 2. Effect of P. niruri extracts and metformin on serum levels of glucose, insulin, HOMA-IR,
FFAs, LDL and TC in HFD-fed rats. (A) Serum levels of glucose; (B) serum levels of insulin; (C) serum
levels of HOMA-IR; (D) serum levels of FFAs; (E) serum levels of LDL; (F) serum levels of TC. (Results
expressed as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01; *** p < 0.001 vs. HFD, and # p < 0.05; ## p < 0.01;
### p < 0.001 vs. NC group). HOMA-IR; homeostatic model assessment of insulin resistance, FFAs; Free
fatty acids, LDL; Low density lipoprotein, TC; Total cholesterol.
Table 1. Effect of P. niruri extracts and metformin on coronary risk indexes.
Parameters NC Group HFD Group HFD + Met HFD + WE HFD + 50% ME HFD + ME
CRI-I = TC/HDL 1.53 ± 0.03 b 4.50 ± 0.57 d 2.40 ± 0.10 3. 3 0.26 d 3.18 ± 0.16 a,d 4.48 ± 0.39 d
CRI-II = LDL/HDL 0.41 ± 0.05 b 5.62 ± 1.10 d 1.42 ± 0.19 b 2.28 ± 0.24 b 1.92 ± 0.17 b 3.29 ± 0.44 a,d
AC = (TC–HDL)/HDL 0.60 ± 0.06 b 6.14 ± 1.18 d 1.64 ± 0.21 b 2.52 ± 0.26 b 2.18 ± 0.16 b 3.93 ± 0.64 a,d
Values are expressed as mean ± SEM a p < 0.05 vs. HFD group; b p < 0.01 vs. HFD group; c p < 0.05 vs. NC group
and d p < 0.01 vs. NC group.
3.4. P. niruri Reduced the Liver Content of TC, TG and Oxidative Stress Indicator
Fat accumulation and lipid peroxidation in liver plays an essential role in the development
of NAFLD [15]. To study the effects of P. niruri extracts on NAFLD progress in HFD-fed rats, we
measured the content of hepatic TC, TG and MDA. High-fat diet caused a significant lipid droplet
a cumulati n. Our results showed considerable incr ase in hepatic content of triglyceri es by 28.9%,
total cholesterol by 50.5% and malondialdehyde (MDA) levels by 78.2% compared to the normal
control group (all p < 0.01). However, hepatic cholesterol levels were significantly reduce by 30.9%,
44%, 43%, and 40.2% after four weeks of oral administration of metformin, WE, 50% ME, and ME of
P. niruri, respectively (all p < 0.01). Moreover, notable decreases in the hepatic triglycerides levels were
observed in animals treated with 50% ME by 28.9% (p < 0.01) and ME by 23.3% (p < 0.05). On the
other hand, the results revealed that the increase in hepatic malondialdehyde has been significantly
inhibited in groups treated with WE by 70% (p < 0.05), 50% ME by 40.1% (p < 0.01) and ME by 38.8%
(p < 0.01) compared with the HFD group (Figure 3).
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Figure 3. Effect of P. niruri extracts and metformin on Hepatic levels of TC, TG and MDA: (A) hepatic 
levels of TC; (B) hepatic levels of TG; (C) hepatic levels of MDA. (Results expressed as mean ± SEM (n 
= 6). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. HFD, and # p < 0.05, ## p ˂ 0.01, ### p < 0.001 vs. NC group). 
TG; triglycerides, MDA; malondialdehyde. 
3.5. Effects of P. niruri on the Liver Histopathology 
Liver biopsy is considered to be the gold standard in NAFLD diagnosis [44]. Therefore, to 
confirm the onset of NAFLD in the animal model, histological analysis was performed as described in 
other studies [45,46]. Steatosis, hepatocyte ballooning and inflammation were assessed and scores 
(Table 2) were given individually. The individual scores were added together to produce the overall 
NAFLD activity score (NAS). 
Table 2. Grading NAFLD activity score (NAS) [47]. 
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<5% (0) None (0) None (0) 0 
5–33% (1) Rare or few (1) 1–2 foci per 20 × field (1) 3 
34–66% (2) Many (2) 2–4 foci/20 × field (2) 6 
>66% (3) Many (2) >4 foci/20 × field (3) 8 
Histological evaluation of liver samples from HFD group showed significant fat deposition with 
highest scores in steatosis, lobular multifocal portal inflammation, hepatocyte ballooning and fibrosis, 
significantly higher than those of the normal control group (p < 0.01). Hence, rats fed the high-fat diet 
developed definite NAFLD. Furthermore, the severe inflammation with fibrosis in the HFD-fed rats 
obviously confirmed the progression from NAFLD to NASH in the HFD group. However, the 
severity of the degenerative changes decreased following four weeks of metformin administration 
and all the P. niruri extracts, which resulted in significant suppression of steatosis, lobular 
inflammation, and NAS, but caused no considerable changes in hepatocyte ballooning (Figure 4 and 
Table 3). 
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a,c 2 ±0 d 4.67 ± 0.42 b,d 
Values are expressed as mean ± SEM a p < 0.05 vs. HFD group; b p < 0.01 vs. HFD group; c p < 0.05 vs. 
NC group and d p < 0.01 vs. NC group. 
Figure 3. Effect of P. niruri extracts and metformin on Hepatic levels of TC, TG and MDA: (A) hepatic
levels of TC; (B) hepatic levels of TG; (C) hepatic levels of MDA. (Results expressed as mean ± SEM
(n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. HFD, and # p < 0.05, ## p < 0.01, ### p < 0.001 vs. NC
group). TG; triglycerides, MDA; malondialdehyde.
3.5. Effects of P. niruri on the Liver Histopathology
Liver biopsy is considered to be the gold standard in NAFLD diagnosis [44]. Therefore, to confirm
the onset of NAFLD in the animal model, histological analysis was performed as described in other
studies [45,46]. Steatosis, hepatocyte ballooning and inflammation were assessed and scores (Table 2)
were given individually. The individual scores were added together to produce the overall NAFLD
activity score (NAS).
Table 2. Grading NAFLD activity score (NAS) [47].
Steatosis Ballooning Lobular Inflammation NAS
<5% (0) None (0) None (0) 0
5–33% (1) Rare or few (1) 1–2 f i per 20 × field (1) 3
34–66% (2) Many (2) 2–4 foci/20 × field (2) 6
>66% (3) Many (2) >4 foci/20 × field (3) 8
Histological valuation of liver samples from HFD group showed significant fat deposition with
highest scores in steatosis, lobular multifocal portal inflammation, hepatocyte ballooning and fibrosis,
significantly higher than those of the normal control group (p < 0.01). Hence, rat fed the high at diet
developed definit NAFLD. Furthermo e, the severe inflammatio with fibrosis in the FD-fed rats
obviously confirm d the progression from NAFLD to NASH in the HFD group. However, the severity
of the deg nerative changes decreased following four weeks of metformin administration and all the
P. niruri extracts, which resulted in significant suppr ssion of teatosis, l bular inflammation, and NAS,
but caused no considerable changes in hepatocyte ballooning (Figure 4 and Table 3).
Table 3. Analysis of N S scores for all groups.
Experimental
Grou Steatosis
Lobular
Inflammation
Hepatocyte
Ba loo S
NC 0 b 0 b 0 b 0 b
HF 3 ± 0 d 1.83 ± 0.17 d 2 0 6.83 . d
HFD + et 1.5 ± 0.34 b,d 0.67 ± 0.21 b 1.8 0.1 d 4 ± .63 b,d
HFD + WE 2 ± 0.26 a,d 1.33 ± 0.33 d 2 ± 0 d 5.33 ± 0.42 a,d
HFD + 50% ME 1.5 ± 0.22 b,d 1 ± 0 a,c 2 ± 0 d 4.5 ± 0.22 b,d
HFD + ME 1.67 ± 0.21 b,d 1 ± 0.26 a,c 2 ± 0 d 4.67 ± 0.42 b,d
Values are expressed as mean ± SEM a p < 0.05 vs. HFD group; b p < 0.01 vs. HFD group; c p < 0.05 vs. NC group
and d p < 0.01 vs. NC group.
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Figure 4. Effect of P. niruri extracts and metformin on the histological evaluation of liver biopsy. 
Typical liver tissue sections (400×) stained with haematoxylin and eosin (H&E). (A) NC group, 
showing normal tissue structure and architecture with no steatosis; (B) HFD group showed vesicular 
steatosis and inflammation (typical NAFLD); (C) HFD + metformin (500 mg/kg); (D) HFD + WE (1000 
mg/kg); (E) HFD + 50% ME (1000 mg/kg) and (F) HFD + ME (1000 mg/kg). The severe hepatic damage 
(inflammation and fibrosis) in HFD rats is further shown in the Figure 4G1,G2 (100×) stained with 
haematoxylin and eosin (H&E), (G1) HFD group showed steatosis (green arrows) with fibrosis (blue 
arrows) (100×); (G2) HFD group showed lobular inflammation (yellow arrows) (100×). 
3.6. In Vitro Tests for the 50% ME of P. niruri 
Our biochemical and histological findings showed that 50% ME of P. niruri exhibited superior 
therapeutic effects among the treated groups. The 50% ME of P. niruri (2.5, 5, 10 and 20 mg/mL) 
exhibited inhibitory activity against the artificially prepared micelles of cholesterol in a dose-
dependent manner by 4.27 ± 0.50%, 5.79 ± 2.10%, 12.03 ± 1.38%, and 12.91 ± 1.17%, respectively, while 
gallic acid (0.2 mg/mL), the standard compound, inhibited the cholesterol micelles’ formation by 23.05 
± 0.40%. The 50% ME of P. niruri also inhibited pancreatic lipase with IC50 value of 0.78 ± 0.05 mg/mL. 
However, it had less potent activity than orlistat which was 0.20 ± 0.01 µg/mL. An α-glucosidase 
inhibitory test demonstrated that 50% ME of P. niruri exhibited a strong inhibitory potential in a 
concentration-dependent manner. The percentage of inhibition ranged from 85.6% for the highest 
concentration (0.156 mg/mL) to 16.9% for the lowest concentration (0.0049 mg/mL). Moreover, the 
magnitude of inhibition of α-glucosidase enzyme activities by 50% ME of P. niruri was comparable to 
the standard inhibitor, acarbose. With reference to the IC50 values, acarbose IC50 was 4.29 ± 0.16 
mg/mL, whereas the IC50 of 50% ME of P. niruri was 0.06 ± 00.0 mg/mL. The findings suggest that the 
inhibitory effects of 50% ME of P. niruri are more potent than acarbose. 
Figure 4. Effect of P. niruri extracts and metformin on the histological evaluation of liver biopsy. Typical
liver tissue sections (400×) stained with haematoxylin and eosin (H&E). (A) NC group, showing
normal tissue structure and architecture with no steatosis; (B) HFD group showed vesicular steatosis
and inflammation (typical NAFLD); (C) HFD + metformin (500 mg/kg); (D) HFD + WE (1000 mg/kg);
(E) HFD + 50% ME (1000 mg/kg) and (F) HFD + ME (1000 mg/kg). The severe hepatic damage
(inflammation and fibrosis) in HFD rats is further shown in the Figure 4G1,G2 (100×) stained with
haematoxylin and eosin (H&E), (G1) HFD group showed steatosis (green arrows) with fibrosis (blue
arrows) (100×); (G2) HFD group showed lobular inflammation (yellow arrows) (100×).
3.6. In Vitro Tests for the 50% ME of P. niruri
Our biochemical and histological findings showed that 50% ME of P. niruri exhibited superior
therapeutic effects among the treated groups. The 50% ME of P. niruri (2.5, 5, 10 and 20 mg/mL)
exhibited inhibitory activity against the artificially prepared micelles of cholesterol in a dose-dependent
manner by 4.27 ± 0.50%, 5.79 ± 2.10%, 12.03 ± 1.38%, and 12.91 ± 1.17%, respectively, while
gallic acid (0.2 mg/mL), the standard compound, inhibited the cholesterol micelles’ formation
by 23.05 ± 0.40%. The 50% ME of P. niruri also inhibited pancreatic lipase with IC50 value of
0.78 ± 0.05 mg/mL. However, it had less potent activity than orlistat which was 0.20 ± 0.01 µg/mL.
An α-glucosidase inhibitory test demonstrated that 50% ME of P. niruri exhibited a strong inhibitory
potential in a concentration-dependent manner. The percentage of inhibition ranged from 85.6%
for the highest concentration (0.156 mg/mL) to 16.9% for the lowest concentration (0.0049 mg/mL).
Moreover, the magnitude of inhibition of α-glucosidase enzyme activities by 50% ME of P. niruri was
comparable to the standard inhibitor, acarbose. With reference to the IC50 values, acarbose IC50 was
4.29 ± 0.16 mg/mL, whereas the IC50 of 50% ME of P. niruri was 0.06 ± 00.0 mg/mL. The findings
suggest that the inhibitory effects of 50% ME of P. niruri are more potent than acarbose.
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3.7. The Effect of Different Doses of 50% ME of P. niruri on NAFLD
As shown in Table 4, all doses of 50% ME significantly decreased serum cholesterol, LDL, CRI-I,
ALT, Insulin concentrations and HOMA-IR and increased the AST/ALT ratio. However, only the dose
of 1000 mg/kg was able to significantly improve the histological parameters (Figure 5).
Table 4. The effect of different doses of 50% ME on NAFLD.
Parameters NC HFD
HFD + 50% ME
1000 mg/kg 500 mg/kg 250 mg/kg
Liver/body weight (%) 2.69 ± 0.21 b 5.80 ± 0.11d 4.22 ± 0.37 a 4.98 ± 0.12 4.79 ± 0.11
Visceral fat/body weight (%) 0.86 ± 0.10 b 1.69 ± 0.16 d 0.82 ± 0.08 b 1.36 ± 0.07 1.32 ± 0.12
Glucose (mmol/L) 4.60 ± 0.27 a 5.42 ± 0.26 c 4.54 ± 0.11 b 4.68 ± 0.10 a 4.80 ± 0.10
TC (mmol/L) 1.64 ± 0.09 b 7.06 ± 0.85 d 4.18 ± 0.39 b 4.64 ± 0.54 b,c 4.76 ± 0.82 b,c
LDL (mmol/L) 0.41 ± 0.02 b 5.92 ± 0.81 d 3.11 ± 0.34 b 3.53 ± 0.49 b,c 3.84 ± 3.84 a,d
LDL/HDL 0.42 ± 0.03 b 6.79 ± 0.57 d 3.27 ± 0.34 a 3.83 ± 0.45 4.54 ± 0.49
CRI-I = TC/HDL 1.66 ± 0.05 b 7.40 ± 0.66 d 4.38 ± 0.26 b 5.26 ± 0.54 a,d 5.76 ± 0.50 a,d
CRI-II = LDL/HDL 0.42 ± 0.03 b 6.79 ± 0.57 d 3.27 ± 0.34 a 3.83 ± 0.45 4.54 ± 0.49
AC = (TC − HDL)/HDL 0.65 ± 0.06 b 6.99 ± 0.58 d 3.37 ± 0.25 a 4.27 ± 0.56 6.47 ± 0.73 d
ALP (IU/L) 230.60 ± 20.18 a 558.20 ± 34.75 c 301.00 ± 9.54 a 316.60 ± 21.76 a 431.00 ± 35.05
ALT (IU/L) 67.20 ± 5.32 b 107.80 ± 12.68 d 65.60 ± 5.90 b 70.60 ± 1.44 b 59.40 ± 2.18 b
AST/ALT 2.39 ± 0.17a 1.31 ± 0.11 c 2.32 ± 0.29 a 2.17 ± 0.08 a 2.23 ± 0.09 a
Insulin (mU/L) 13.40 ± 0.74 b 44.67 ± 1.06 d 14.86 ± 0.84 b 15.34 ± 0.64 b 19.26 ± 1.23 b
HOMA-IR 2.73 ± 0.19 b 10.90 ± 0.41 d 2.99 ± 0.16 b 3.19 ± 0.16 b 4.10 ± 0.23 b
Steatosis 0.00 ± 0.00 b 3.00 ± 0.00 d 1.20 ± 0.20 b 1.40 ± 0.24 a 1.80 ± 0.20
Lobular inflammation 0.00 ± 0.00 b 2.00 ± 0.00 d 1.00 ± 0.00 a 1.20 ± 0.20 1.20 ± 0.20
Hepatocyte ballooning 0.00 ± 0.00 b 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00
NAS 0.00 ± 0.00 b 7.00 ± 0.00 d 4.20 ± 0.20 a,c 4.60 ± 0.24 d 5.20 ± 0.37 d
Results are expressed as mean ± SEM, compared to HFD group. a p < 0.05 vs. HFD group; b p < 0.01 vs. HFD group;
c p < 0.05 vs. normal group; d p < 0.01 vs. normal group.
Nutrients 2017, 9, 766 10 of 12 
3.7. The Effect of Different Doses of 50% ME of P. niruri on NAFLD 
As shown in Table 4, all doses of 50% ME significantly decreased serum cholesterol, LDL, CRI-I, 
ALT, Insulin concentrations and HOMA-IR and increased the AST/ALT ratio. However, only the dose 
of 1000 mg/kg was able to significantly improve the histological parameters (Figure 5). 
Table 4. The effect of different doses of 50% ME on NAFLD. 
Parameters  NC HFD  
HFD + 50% ME 
1000 mg/kg 500 mg/kg 250 mg/kg
Liver/body weight (%) 2.69 ± 0.21 b 5.80 ± 0.11d 4.22 ± 0.37 a 4.98 ± 0.12 4.79 ± 0.11 
Visceral fat/body weight (%) 0.86 ± 0.10 b 1.69 ± 0.16 d 0.82 ± 0.08 b 1.36 ± .07 1.32 ± 0.12 
Glucose (mmol/L) 4.60 ± 0.27 a 5.42 ± 0.26 c 4.54 ± 0.11 b 4.68 ± 0.10 a 4.80 ± 0.10 
TC (mmol/L) 1.64 ± 0.09 b 7.06 ± 0.85 d 4.18 ± .39 b 4.64 ± 0.54 b,c 4.76 ± 0.82 b,c 
LDL (mmol/L) 0.41 ± 0.02 b 5.9  ± 0.81 d 3.11 ± .34 b 3.53 ± 0.49 b,c 3.8  ± 3.84 a,d 
LDL/HDL 0.42 ± 0.03 b 6.79 ± 0.57 d 3.27 ± 0.34 a 3.83 ± 0.45 4.54 ± 0.49 
CRI-I = TC/HDL 1.66 ± 0.05 b 7.40 ± 0.66 d 4.38 ± 0.26 b 5.26 ± 0.54 a,d 5.76 ± 0.50 a,d 
CRI-II = LDL/HDL 0.42 ± 0.03 b 6.79 ± 0.57 d 3.27 ± 0.34 a 3.83 ± 0.45 4.54 ± 0.49 
AC = (TC − HDL)/HDL 0.65 ± 0.06 b 6.99 ± 0.58 d 3.37 ± 0.25 a 4.27 ± 0.56 6.47 ± 0.73 d 
ALP (IU/L) 230.60 ± 20.18 a 558.20 ± 34.75 c 301.00 ± 9.54 a 316.60 ± 21.76 a 431.00 ± 35.05 
ALT (IU/L) 67.20 ± 5.32 b 107.80 ± 12.68 d 65.60 ± 5.90 b 70.60 ± 1.44 b 59.40 ± 2.18 b 
AST/ALT 2.39 ± 0.17a 1.31 ± 0.11 c 2.32 ± 0.29 a 2.17 ± 0.08 a 2.23 ± 0.09 a 
Insulin (mU/L) 13.40 ± 0.74 b 44.67 ± 1.06 d 14.86 ± 0.84 b 15.34 ± 0.64 b 19.26 ± 1.23 b 
HOMA-IR 2.73 ± 0.19 b 10.90 ± 0.41 d 2.99 ± 0.16 b 3.19 ± 0.16 b 4.10 ± 0.23 b 
Steatosis 0.00 ± 0.00 b 3.0  ± 0.00 d 1.20 ± .20 b 1.40 ± 0.24 a 1.80 ± 0.20 
Lobular infl mmation 0.00 ± 0.00 b 2.0  ± 0.00 d 1.00 ± .00 a 1.20 ± 0.20 1.20 ± 0.20 
Hepatocyte ballooning 0.00 ± 0.00 b 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 2.00 ± 0.00 
NAS 0.00 ± 0.00 b 7.00 ± 0.00 d 4.20 ± 0.20 a,c 4.60 ± 0.24 d 5.20 ± 0.37 d 
Results are expressed as mean ± SEM, compared to HFD group. a p < 0.05 vs. HFD group; b p 
< 0.01 vs. HFD group; c p < 0.05 vs. normal group; d p < 0.01 vs. normal group. 
 
Figure 5. Microscopic examination of liver tissues stained with H&E after four-week treatment with 
different doses of 50% ME under 100× magnification. (A) Normal tissue structure; (B) steatosis, severe 
inflammation and fibrosis in HFD group; (C) marked reduction of NAFLD pathological 
manifestations at dose 1000 mg/kg of 50% ME; (D) moderate steatosis and inflammation at dose 500 
mg/kg of ME50; (E) severe inflammation at the dose 250 mg/kg of ME 50 (green arrows: steatosis; 
yellow arrows: inflammation, blue arrows: fibrosis). 
Figure 5. Microscopic examination of liver tissues stained with H&E after four-week treatment with
different doses of 50% ME under 100× magnification. (A) Normal tissue structure; (B) steatosis, severe
inflammation and fibrosis in HFD group; (C) marked reduction of NAFLD pathological manifestations
at dose 1000 mg/kg of 50% ME; (D) moderate steatosis and inflammation at dose 500 mg/kg of ME50;
(E) severe inflammation at the dose 250 mg/kg of ME 50 (green arrows: steatosis; yellow arrows:
inflammation, blue arrows: fibrosis).
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3.8. Total Phenolic Content (TPC), Total Flavonoid Content (TFC) and Anti-Oxidative Activities of P. niruri
The highest total phenolic and flavonoid contents were found in 50% ME of P. niruri with the
highest antioxidant activities in DPPH and ABTS tests (Table 5).
Table 5. Anti-oxidative activities and phytochemical screening of P. niruri extracts.
Total Phenolic
(µg Gallic Acid
Equiv./mg
Extract)
Total Flavonoid
(µg Quercetin
Equiv./mg
Extract)
DPPH IC50
(µg/mL)
ABTS IC50
(µg/mL)
FRAP (nmol
Fe+2 Equiv./mg
Extract)
WE 224.13 ± 1.14 39.41 ± 0.72 7.38 ± 0.84 31.94 ± 1.36 272.56 ± 4.39
50% ME 323.98 ± 0.33 64.46 ± 1.36 2.72 ± 0.25 26.51 ± 0.63 220.01 ± 1.90
ME 237.87 ± 0.46 49.85 ± 0.62 8.32 ± 0.29 99.66 ± 0.98 333.95 ± 11.73
Ascorbic acid
(Standard) — — 1.51 ± 0.22 5.73 ± 0.09 —
Values are expressed as mean ± SEM (n = 3). DPPH; 2,2-diphenyl-1-picrylhydrazyl, ABTS; 2,2-azinobis
(3-ethyl-benzothiazoline-6-sulfonic acid) and FRAP; ferric reducing antioxidant power.
3.9. Extract Standardization by HPLC Analysis
All selected marker compounds showed good linear regression with high correlation coefficient
values (R2 ≥ 0.999) between the peak area and the concentration. LOD was 0.20 and 0.52 µg/mL,
respectively; and LOQ values were 0.78 and 1.56 µg/mL, respectively, for ellagic acid and phyllanthin.
Figure 6 shows a representative HPLC chromatogram of mixed standard compounds. Peaks appeared
at 6.33 min for ellagic acid and at 15.95 min for phyllanthin. The recovery percentages for the
selected marker compounds in P. niruri extract are presented in Table 6. Recovery values for the
concentrations used ranged from 99.25% to 104.75% and from 100.04% to 102.65% for ellagic acid and
phyllanthin, respectively. The recovery data were deemed satisfactory, leading to the conclusion that
our extraction methodology did not cause substantial loss of those compounds. Data pertaining to the
intra- and inter-day accuracy and precision obtained after analysing the selected marker compounds are
summarised in Table 6. The accuracy values, expressed as percentages of the true values, were 95.90%
and 104.94% for ellagic acid and phyllanthin, respectively. The corresponding precision values, expressed
as CV%, totalled 0.18% and 4.78% for intra-day and inter-day analyses, respectively. This indicated
that the method used was reliable and reproducible. Ellagic acid and phyllanthin were quantified in
P. niruri using the HPLC technique described earlier. The HPLC chromatogram of P. niruri extract is
shown in Figure 7. The HPLC-UV method used here was developed for simultaneous determination of
ellagic acid and phyllanthin. Analysis revealed that that P. niruri contained several peaks at different
retention times, demonstrating that multiple components were detected. However, the retention times of
ellagic acid and phyllanthin were approximately 6.32–15.92 min. Both ellagic acid and phyllanthin were
major compounds in P. niruri extract, with phyllanthin making up over 10% and ellagic acid comprising
nearly 2% of the extract. We believe that the HPLC method used in this work can be used as a standard
analytical method for the quantification of marker compounds in P. niruri extract.
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Table 6. Percentage recovery, within-day and between-day precision and accuracy values for ellagic
acid and phyllanthin in P. niruri extract.
Compounds Concentrations(µg/mL)
Within-Day Between-Day Recovery
Accuracy
(%)
Precision
(CV%)
Accuracy
(%)
Precision
(CV%) Mean (%)
Mean
(CV%)
Ellagic acid
50.00 100.30 0.18 100.01 0.27 99.25 0.80
6.25 97.50 0.19 97.66 2.64 - -
3.12 102.18 0.26 100.50 2.09 104.75 2.18
1.56 104.36 0.51 100.64 2.83 - -
0.78 104.62 0.67 104.89 4.15 103.62 3.90
Phyllanthin
25.00 96.28 0.25 98.47 1.82 102.65 1.19
1 . 0 104.94 1.28 102.50 3.27 - -
6.25 104.42 4.78 100.42 1.45 100.04 1.49
3.12 100.83 0.28 101.10 2.63 - -
1.56 95.90 2.04 98.35 4.77 101.31 3.41
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4. Discussion
Sedentary lifestyle and overconsumption of high-calorie foods are the main reasons for central
obesity and NAFLD [48]. The present study provides strong evidence of the anti-NAFLD activity of P.
niruri in SD rats. Our optimized extract of P. niruri not only supressed hepatic fat accumulation but also
blocked inflammation in NAFLD rats, thus preventing fibrosis and inhibiting simple steatosis from
progressing to NASH. Additionally, rats treated with P. niruri exhibited significantly lower indicators
of atherosclerosis than untreated rats.
Our current in vivo model of NAFLD was successfully established and developed to NASH after
feeding the rats with a HFD enriched with trans-fatty acids from margarine, and saturated fatty acids
derived from animal fat [49,50]. The high increase in the weight of the liver and visceral fat in the HFD
group is a prominent feature of NAFLD [51,52]. Furthermore, the hypercholesterolemia within HFD
group was previously reported in 20–80% of human NAFLD cases [53], and a greater concentration of
serum FFAs is correlated with disease severity [54]. Moreover, the significant increase in serum levels
of ALP and ALT in addition to the elevated hepatic content of TG, TC and MDA in NAFLD rats is a
strong indicator of liver damage and oxidative stress [55]. According to the “two hit” hypothesis of
NAFLD, high levels of free fatty acids lead to lipogenesis and lipid accumulation in the liver during the
first hit of NAFLD progress, whereas the presence of oxidative stress and lipid peroxidation represents
the second hit [56]. More specifically, the accumulated fats in the liver induce the release of cytotoxic
oxygen free radicals, which are associated with lipid peroxidation markers such as malondialdehyde
(MDA) [57] that trigger inflammation and fibrosis [58,59]. In the current study, HFD group exhibited
higher concentrations of glucose and hyperinsulinemia, elevated HOMA-IR values, and developed
significant hepatic steatosis, inflammation and fibrosis. These results are in agreement with previous
studies and further prove the ability of a HFD to cause rapid fat accumulation in the liver, with distinct
elevation in insulin resistance (HOMA-IR values) [60]. The increase of insulin resistance in the HFD
group would stimulate oxidative stress in the liver by releasing reactive oxygen species, causing
hepatic lipid peroxidation and initiating inflammatory reactions that enhance fibrosis through the
activation of hepatic stellate cell (HSC) [3,61].
In addition, the significant increase in serum uric acid (SUA) concentration in the HFD group led
to the development of NAFLD and insulin resistance. It was reported that hyperuricemia is closely
correlated with the severity of liver damage. Moreover, SUA can enhance inflammatory reactions and
trigger oxidative stress in adipocytes, which in turn increases insulin resistance and induces more
lipolysis in adipose tissue and greater oxidative stress in the liver cells [62]. Consequently, the reduction
in SUA could improve NAFLD [63]. Similarly, the present findings suggest that decreasing the SUA
level in WE- and ME-treated groups contributed to the suppression of NAFLD in these groups.
The considerable increase in serum atherogenic indexes indicates a higher risk of atherosclerosis
in NAFLD rats. This is attributed to the sharp increase in serum levels of LDL, which is usually
oxidized to form the peroxides that play a role in several atherosclerotic stages by their cytotoxic
effects, leading to endothelial injury [64].
However, 50% ME of P. niruri was the most active among the three extracts of the plant. It prominently
decreased visceral adipose tissue and liver weight, and blocked the progress of NAFLD by the reduction
in hepatic steatosis and inflammation. In addition to preventing fibrosis, it improved liver function and
decreased serum levels of glucose, insulin concentrations and HOMA-IR, indicating a significant decrease
in insulin resistance. It was obvious from the results that P. niruri improved cross-talk between the liver
and adipose tissues. This was reflected by the lower serum concentrations of TC, LDL and FFAs in
NAFLD rats [65]. The 50% ME of P. niruri also supressed FFA-evoked de novo lipogenesis in the liver
and decreased the hepatic content of cholesterol, TG, and MDA. As a result, the atherogenic ratios were
evidently decreased. The results show that all doses (1000 mg/kg, 500 mg/kg, and 250 mg/kg) of 50% ME
are able to significantly reduce atherogenic ratios, ALT, AST/ALT ratio, and suppress insulin resistance.
On the other hand, liver weight, visceral adipose tissue weight and liver histology were only improved by
the dose of 1000 mg/kg, indicating that this is the anti-NAFLD effective dose.
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The anti-NAFLD effect of P. niruri is likely to result from the antioxidant activity shown by DPPH
and ABTS tests. This is most likely attributable to phenolic compounds in all P. niruri extracts that
inhibited oxidative stress by decreasing lipid peroxidation and improving insulin signalling and
β-oxidation. These results are in agreement with many previous studies that explained the potent
antioxidant activities of polyphenols in suppressing lipogenesis and inhibiting fatty acid synthesis
in vitro [14]. The anti-NAFLD effect of 50% ME of P. niruri may also be due to ellagic acid, an active
antioxidant that was a major compound in the extract. It was previously found to be responsible for
anti-NAFLD effect of Phyllanthus emblica L. in vitro [66]. Ellagic acid was further reported to decrease
de novo lipogenesis, inhibit TG esterification and enhance FFAs oxidation by increasing the expression
of FFAs oxidative genes in the liver, leading to significant reduction of hepatic lipid accumulation [67].
It was suggested that this activity is due to the increase in energy expenditure by enhancing AMPK,
the regulator of energy homeostasis and FFAs oxidation [68]. It is anticipated that 50% ME of P. niruri
might act by a similar mechanism.
Another anti-oxidant agent and bioactive compound in 50% ME of P. niruri is phyllanthin, which
has been reported to be effective in ameliorating the development of NAFLD in mice [69]. The other
possible mechanism that might contribute to the anti-NAFLD effect of 50 ME of P. niruri is inhibiting
the activities of α-glucosidase, pancreatic lipase and cholesterol micellization. Since high rates of
carbohydrate and fat consumption increase insulin resistance and oxidative stress [70], improving
insulin signalling can be achieved by decreasing the intake of carbohydrates and lipids, and attenuating
the postprandial hyperlipidemia. This might contribute by decreasing the hepatic cholesterol and FFAs
pool required for the de novo lipogenesis process in the liver [71–73]. The same mechanism was also
suggested for acarbose, orlistat and ezetimibe as a prospective treatment for lipid metabolic disorders
such as obesity and other insulin resistance complications including NAFLD and diabetes [59,74,75].
The oral consumption of P. niruri is considered safe, and investigations into its toxicity in female
Sprague–Dawley rats have not shown any abnormality in different body organs. The LD50 was higher
than 5000 mg/kg body weight [76]. Moreover, it is noteworthy that P. niruri was clinically approved to
be safely consumed by children [77].
In summary, 50% ME of P. niruri reduced visceral adiposity, improved liver enzymes abnormalities,
and decreased hepatic lipid peroxidation and fat accumulation. It also decreased the risk of
atherosclerosis related to NAFLD, induced by a high-fat diet in SD rats. The data suggest that the
antioxidant and hypolipidemic effects of the bioactive components in 50% ME of P. niruri (ellagic acid
and phyllanthin) play essential roles in the therapeutic properties. Hence, the current study established
the first-ever report on the potential therapeutic use of P. niruri as a natural source for treating NAFLD.
The general mechanism of anti-NAFLD effect of action of P. niruri is shown in Scheme 1.
High dietary fat consumption combines with an increased rate of lipolysis in the insulin-resistant
adipose tissues, leading to elevated free fatty acid (FFAs) concentrations in the blood. The excessive free
fatty acids are delivered to the insulin-resistant liver, which has impaired mitochondrial β-oxidation.
Excessive intake of carbohydrates, along with insulin resistance, result in channelling high quantities
of glucose to the liver, where it is converted to either glycogen or FFAs via insulin-stimulated de
novo lipogenesis (DNL), leading to excessive accumulation of triglycerides and cholesterol in the
liver. P. niruri decreased insulin resistance, reduced serum fatty acids, and inhibited α-glucosidase,
pancreatic lipase and cholesterol micellization, leading to a decrease in the amounts of glucose and
FFAs in the liver. Consequently, fewer FFAs and less glucose will be available to the de novo lipogenesis
process, and therefore less fat will accumulate in the liver. P. niruri also reduced hepatic MDA, the
marker of lipid peroxidation, which stimulates hepatic stellate cells (HSC), the main cells that are
responsible for triggering fibrosis in the liver. As a result, P. niruri reduced hepatic fibrosis.
The yellow arrows denote the weakened pathway in NAFLD, while the black arrows refer to the
stimulated pathway in NAFLD. The blue symbol indicates the inhibitory effect of P. niruri.
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